Date: 2017-10-26
Type of information: Opening of new premises
Compound: manufacturing facility and office space in Lexington
Company: Wave LIfe Sciences (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: opening of new premises
Action mechanism:
Disease:
Details:
- • On October 26, 2017, Wave Life Sciences announced the public opening of its new 90,000 square foot state-of-the-art manufacturing facility and office space in Lexington, Massachusetts.
- Wave's expansion into this new manufacturing facility is part of a long-term strategy of platform sustainability and independence. The new facility is designed to support the company’s robust and rapidly advancing clinical pipeline of drug candidates, which originates from its proprietary stereopure nucleic acid drug development platform.
- With six clinical programs expected to be initiated by the end of 2018, these enhanced manufacturing capabilities are expected to provide Wave with greater independence and flexibility in conducting clinical trials, and the potential to bring disease-modifying drugs to patients in a potentially expedited fashion.
- The three-story facility is designed to be good manufacturing practice (GMP) certified and to have oligonucleotide synthesis capacity ranging from high throughput to large scale production. The new lab space is designed to meet the synthesis demands of Wave’s growing portfolio, while also increasing control and visibility of its product supply chain.
- Wave’s Lexington facility is designed for capacity of approximately 200 employees over the long term, with the majority of the space dedicated to manufacturing and laboratories. The space is also intended for non-manufacturing employees and was designed to support the company’s continued expansion. The company's corporate U.S. headquarters and initial laboratories are located in its nearby Cambridge, MA facility.
Financial terms:
Latest news:
Is general: Yes
